In summary, our finding of frequent PD-L1/PD-L2 discordance in BC supports the potential value of PD-L2 as a complementary marker when evaluating breast tumors for immune checkpoint inhibitor therapy. The gene discussed is PDCD1LG2; the disease is breast cancer.